@article{e1fface0e13a45f2b04fdc9aa96bf4b9,
title = "Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration",
abstract = "Memantine's benefits in Alzheimer's disease (AD) are modest and heterogeneous. We tested the feasibility of using sensitivity to acute memantine challenge to predict an individual's clinical response. Eight participants completed a double-blind challenge study of memantine (placebo versus 20 mg) effects on autonomic, subjective, cognitive, and neurophysiological measures, followed by a 24-week unblinded active-dose therapeutic trial (10 mg bid). Study participation was well tolerated. Subgroups based on memantine sensitivity on specific laboratory measures differed in their clinical response to memantine, some by large effect sizes. It appears feasible to use biomarkers to predict clinical sensitivity to memantine.",
keywords = "Alzheimer's disease, event-related potentials, memantine, neurocognition, prepulse inhibition",
author = "Swerdlow, {Neal R.} and Kotz, {Juliana E.} and Joshi, {Yash B.} and Jo Talledo and Joyce Sprock and Molina, {Juan L.} and Branko Huisa and Huege, {Steven F.} and Romero, {Jairo Alberto} and Walsh, {Michael J.} and Lisa Delano-Wood and Light, {Gregory A.} and Joseph Quinn",
note = "Funding Information: This search for predictive biomarkers is largely agnostic to mechanism. Our preliminary results suggest that even low-tech subjective ratings after a MEM challenge might identify individuals most likely to benefit clinically from this medication. For example, subjects who correctly identified their active pill day (presumably reflecting subjective awareness of active drug) benefitted most from MEM over the 24-week trial, with medium-to-large effect Research was supported by the National Institute on Aging (AG059640) and the National Institute of Mental Health (MH094320). Help with recruitment was provided by the Shiley-Marcos Alzheimer{\textquoteright}s Disease Research Center (National Institute on Aging, P30AG062429). Most excellent manuscript assistance was provided by Ms. Maria Bongiovanni. Publisher Copyright: {\textcopyright} 2021 - IOS Press. All rights reserved.",
year = "2021",
doi = "10.3233/JAD-215029",
language = "English (US)",
volume = "84",
pages = "1431--1438",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",
}